{
    "clinical_study": {
        "@rank": "144663", 
        "arm_group": [
            {
                "arm_group_label": "IQP-AS-105", 
                "arm_group_type": "Active Comparator", 
                "description": "One tablet daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One tablet daily"
            }
        ], 
        "brief_summary": {
            "textblock": "IQP-AS-105, is a food supplement derived from garlic (Allium sativum). The objective of this\n      study is to evaluate the possibilities of clinical use of IQP-AS-105 as a preventive\n      medicine, based on its ability to enhance the immune system responses"
        }, 
        "brief_title": "Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Common Cold", 
            "Upper Respiratory Tract Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Common Cold", 
                "Disease Susceptibility", 
                "Respiratory Tract Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-70 years\n\n          -  increased risk for infections - at least 4 cold episodes within 12 months\n\n          -  commitment to adhere to their accustomed diet and physical activity\n\n          -  women of child-bearing potential have to agree to use appropriate birth control\n             methods\n\n          -  written consent of the subject to participate is a prerequisite for study\n             participation\n\n        Exclusion Criteria:\n\n          -  acute / chronic upper airways disease\n\n          -  chronic cough of any origin\n\n          -  acute / chronic lower airways disease\n\n          -  any allergic reaction that may influence the study outcome (e.g. acute/chronic\n             rhinitis)\n\n          -  history of nasal reconstructive surgery\n\n          -  presence of nasal ulcers or nasal polyps\n\n          -  severe nasal septum deviation or other condition that could cause nasal obstruction\n\n          -  congenital or acquired immunodeficiency disease (e.g. HIV infection)\n\n          -  severe organ or systemic diseases\n\n          -  body temperature above 37.5\u00b0C\n\n          -  suspected swine flu or influenza\n\n          -  vaccination against influenza or swine flu within 3 months prior to study start\n\n          -  stomach/gastrointestinal diseases\n\n          -  sleep disorder\n\n          -  psychiatric disorders\n\n          -  known sensitivity to the ingredients of the investigational product\n\n          -  intake of products that may influence the study outcome within the last 14 days prior\n             to study start and during the study\n\n          -  analgesics , antibiotics or decongestant nose drops/spray, unless they are used as\n             rescue medications\n\n          -  pregnancy or nursing\n\n          -  alcohol / drug abuse\n\n          -  simultaneous participation in another clinical trial or participation in a clinical\n             trial within the last 30 days\n\n          -  insufficient compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "312", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964885", 
            "org_study_id": "INQ/012213"
        }, 
        "intervention": [
            {
                "arm_group_label": "IQP-AS-105", 
                "intervention_name": "IQP-AS-105", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "ubongartz@analyze-realize.com", 
                "last_name": "Udo Bongartz, PhD", 
                "phone": "+49 30/306 40 20 543"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10369"
                }, 
                "name": "Udo Bongartz"
            }, 
            "investigator": {
                "last_name": "Udo Bongartz, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial to Explore Benefit and Tolerability of IQP-AS-105 (Xaludicin\u00ae) in Subjects With Increased Susceptibility to Upper Respiratory Tract Infections", 
        "overall_contact": {
            "email": "ubongartz@analyze-realize.com", 
            "last_name": "Udo Bongartz, PhD", 
            "phone": "+49 30/306 40 20"
        }, 
        "overall_official": {
            "last_name": "Udo Bongartz, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed by WURSS-21", 
            "measure": "Difference in severity of common cold symptoms for cold episodes between the two arms", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of cold episodes", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Duration of cold episodes", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold symptoms over the first 4 days of the episode", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold symptoms over the first 7 days of the episode", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Day and score value of the maximal WURSS-21 daily score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold somptoms from the date of the maximal WURSS-21 daily score, for 4 days following thereafter", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Incidence of viral infection", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Use of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of days on sick leave related to cold episodes", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of re-infections", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold symptoms at first episode", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold symptoms at recurring (subsequent) episodes", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Severity of cold episodes during the 4 week follow-up period", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes in special laboratory parameters in the subgroup", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Changes in cytokine production in the subgroup", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "global evaluation of the benefit by the subjects / investigators", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Global assessment of tolerability by subjects/investigators", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}